文献速递创伤与烧伤重症综合管理与镇静镇痛

骨科创伤术后出院后静脉血栓栓塞预防:阿司匹林与依诺肝素的持续争论

Aspirin versus enoxaparin for postdischarge venous thromboembolism prophylaxis following orthopedic trauma surgery: An ongoing debate.
PubMed 文献 · J Trauma Acute Care Surg · 2026-07-24
一句话结论回顾性队列显示骨科创伤术后出院用阿司匹林相比依诺肝素与90天VTE风险显著升高相关(OR 4.704)。

该回顾性队列研究纳入2020-2024年一家一级创伤中心收治的982例成人下肢或骨盆骨科损伤并接受手术固定的患者,比较出院后使用阿司匹林(456例)与依诺肝素(526例)进行VTE预防的结局。经逆概率加权和双稳健逻辑回归控制混杂因素后,出院阿司匹林相比低分子肝素与90天出院后VTE风险显著升高相关(OR 4.704;95%CI 1.332-16.612;P=0.016)。90天再入院和死亡率两组无显著差异。研究结论认为低分子肝素与更低的出院后VTE风险相关,但需进一步研究明确基于合并症和损伤模式的最佳预防策略。

要点

  • 骨科创伤术后出院用阿司匹林相比依诺肝素,90天VTE风险显著升高(OR 4.704;95%CI 1.332-16.612;P=0.016)。
  • 该结果为回顾性队列研究的关联,非因果结论,不能直接推广为所有骨科创伤患者必须用依诺肝素。
  • 90天再入院和死亡率在阿司匹林与依诺肝素组间无显著差异。
  • 研究排除入院前6个月内已有VTE或正在接受治疗性抗凝/抗血小板治疗的患者。
  • 证据等级为Level 3(回顾性、治疗/管理类),需前瞻性研究确认。

适用人群与场景

  • 成人(≥18岁)下肢或骨盆骨科损伤并接受手术固定的患者,来自一家一级创伤中心2020-2024年创伤登记数据。
  • 排除标准:入院前6个月内记录有VTE或正在接受治疗性抗凝/抗血小板治疗的患者。
  • 场景为出院后VTE预防,非急诊或ICU床旁急性期决策。

诊断标准与关键阈值

  • 主要结局为90天出院后VTE,定义为深静脉血栓或肺栓塞。
  • 原文未提及具体的VTE诊断标准或筛查方案。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或疗程。
  • 比较的出院预防方案为阿司匹林 vs 依诺肝素(低分子肝素),选择因患者和损伤因素而异。

红旗征与不能漏的情况

  • 原文未提及红旗征或需要立刻处理的情况。

研究设计与关键结果

  • 研究类型:单中心回顾性队列研究,样本量982例,来自一家一级创伤中心。
  • 人群:成人下肢或骨盆骨科损伤并接受手术固定的患者;出院阿司匹林456例(46.4%),出院依诺肝素526例(53.6%)。
  • 主要终点:90天出院后VTE,阿司匹林相比依诺肝素OR 4.704(95%CI 1.332-16.612;P=0.016)。
  • 关键次要终点:90天再入院和死亡率两组无显著差异。
  • 统计方法:逆概率加权和双稳健逻辑回归,控制年龄、性别、BMI、损伤严重度评分、住院时长、合并症和骨折部位。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(治疗/管理类),证据等级Level 3。
  • 局限:单中心、回顾性设计,原文未提及开放标签或样本量计算;结论需进一步前瞻性研究验证。

对床旁实践的改变

  • 对于成人下肢或骨盆骨科损伤术后出院患者,选择阿司匹林而非依诺肝素进行VTE预防可能与更高的90天VTE风险相关,应结合个体合并症和损伤模式权衡。
  • 该证据为回顾性关联,不能直接改变为强制使用依诺肝素,但提示出院时选择阿司匹林需谨慎评估VTE风险。
  • 不适用于入院前6个月内已有VTE或正在接受治疗性抗凝/抗血小板治疗的患者。

指南或共识出处

  • J Trauma Acute Care Surg 2026;00:000-000

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Accepted venous thromboembolism (VTE) prophylaxis after orthopedic trauma includes anticoagulants and aspirin, with selection varying by patient and injury factors. This study evaluates a single institution's outcomes after transitioning from low-molecular-weight heparin to aspirin for postdischarge prophylaxis.

METHODS: This retrospective cohort study of adult patients (≥18 years) with lower extremity or pelvic orthopedic injuries who underwent operative treatment between 2020 and 2024 was identified from the trauma registry of a Level-1 trauma center. Patients were included if they underwent operative fixation during the index hospitalization. Exclusion criteria included a documented VTE or receipt of therapeutic anticoagulation/antiplatelet therapy within six months before admission. The primary outcome was 90-day postdischarge VTE, defined as deep vein thrombosis or pulmonary embolism. Secondary outcomes included 90-day readmission and mortality. Inverse probability of treatment weighting and doubly robust logistic regression were used to compare discharge chemoprophylaxis regimens (aspirin vs. enoxaparin), controlling for age, sex, body mass index, injury severity score, length of stay, comorbidities, and fracture location.

RESULTS: A total of 982 patients met inclusion criteria, including 456 (46.4%) patients discharged on aspirin and 526 (53.6%) patients discharged on enoxaparin. Among orthopedic trauma patients, discharge aspirin was associated with significantly higher odds of 90-day postdischarge VTE compared with low-molecular-weight heparin (OR, 4.704; 95% CI, 1.332-16.612; p = 0.016). No significant differences were observed between discharge chemoprophylaxis groups with respect to 90-day readmission or mortality.

CONCLUSIONS: Low-molecular-weight heparin was associated with lower odds of postdischarge VTE compared with aspirin in this retrospective cohort of orthopedic trauma patients. Further investigation is needed to better define the optimal postdischarge prophylaxis strategy based on individual patient comorbidities and injury patterns. (J Trauma Acute Care Surg 2026;00:000-000. Copyright © 2026 Wolters Kluwer Health, LLC. All rights reserved.).

LEVEL OF EVIDENCE: Retrospective, Therapeutic/Care Management; Level 3.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Gangavaram A, Mahatme RJ, Gerak SK, et al. Aspirin versus enoxaparin for postdischarge venous thromboembolism prophylaxis following orthopedic trauma surgery: An ongoing debate. J Trauma Acute Care Surg. 2026. PMID: 42497355. doi:10.1097/TA.0000000000005124

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。